Pharmacological Induction of a Progenitor State for the Efficient Expansion of Primary Human Hepatocytes

Carmen Unzu, Evarist Planet, Nathalie Brandenberg, Floriane Fusil, Marco Cassano, Jimena Perez‐Vargas, Marc Friedli, François‐Loïc Cosset, Matthias P. Lutolf, Barbara E. Wildhaber, Didier Trono – 14 December 2018 – The liver is an organ with strong regenerative capacity, yet primary hepatocytes have a low amplification potential in vitro, a major limitation for the cell‐based therapy of liver disorders and for ex vivo biological screens.

Porphyromonas gingivalis as a Possible Risk Factor in the Development/Severity of Acute Alcoholic Hepatitis

Yun Zhou, Vatsalya Vatsalya, Leila Gobejishvili, Richard J. Lamont, Craig J. McClain, Wenke Feng – 14 December 2018 – Bacterial infection is frequently observed in patients with alcoholic liver disease (ALD). We examined a possible role of Porphyromonas gingivalis in the development/progression and severity of disease in patients with acute alcoholic hepatitis (AAH). Plasma specimens from 47 patients with AAH (16 moderate, Model for End‐Stage Liver Disease [MELD] score <20]; 31 severe, MELD score >20) and 22 healthy controls (HCs) were collected.

Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials

Elizabeth M. Brunt, David E. Kleiner, Laura A. Wilson, Arun J. Sanyal, Brent A. Neuschwander‐Tetri, for the Nonalcoholic Steatohepatitis Clinical Research Network – 14 December 2018 – Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with nonalcoholic steatohepatitis (NASH).

Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection

Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.

Subscribe to